EUCTR2007-005941-39-GB进行中（未招募）1 期
An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Patient has histologically or cytologically documented, unresectable, locally advanced
- •or metastatic Stage IIIB/IV NSCLC that has relapsed after
- •chemotherapy/chemoradiotherapy.
- •2. Patient has a pre-study, diagnostic formalin fixed paraffin-embedded tumor tissue
- •sample available for correlative studies.
- •- Sample is OPTIONAL in the Phase I portion of the study.
- •- Sample is REQUIRED in the Phase II portion of the study.
- •3. Patient has measurable disease based on RECIST criteria.
- •4. Patient has had at least one systemic chemotherapy regimen for recurrent or
- •metastatic disease.
- •5. Patient is male or female, and 18 years of age on the day of signing informed
- •6. Patient has a performance status 0-2 on the ECOG Performance Scale.
- •7. Patient must have adequate organ function as indicated by the following laboratory values:
- •- ANC greater than or equal to 1,500/µl; Platelet greater than or equal to 100,000/ µl; Hemoglobin greater than or equal to 9 g/dL; Creatinine <1.5mg/ml; T.bilirubin = ULN, AST/ALT = 1.5x ULN, etc.
- •8. Female patient of childbearing potential has a negative serum/urine pregnancy test at
- •9. Male and female patients, as well as their partners, must agree to use adequate
- •contraception during therapy with MK-0646 alone or in combination with erlotinib.
- •Note that simultaneous use of two reliable forms of contraception is recommended for the entire study period and ending 28±2 days after the last dose of study drug.
- •10. Patient, or the patient's legal representative, has voluntarily agreed to participate by giving written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patient who has had chemotherapy or therapeutic radiotherapy within 2 weeks, or
- •biological therapy such as bevacizumab (Avastin ) within 4 weeks, prior to entering
- •the study or who has not recovered from adverse events due to agents administered
- •more than 4 weeks earlier to at least grade 1 or baseline.
- •2. Patient who has received prior EGFR TKI inhibitor/anti-EGFR mAb therapy or
- •prior IGF-1R - TKI inhibitor/anti-IGF-1R mAb therapy.
- •3. Patient who has received more than 2 prior systemic chemotherapy regimens for
- •recurrent or metastatic disease.
- •4. Patient who has not completed radiotherapy with complete resolution of toxicities at
- •least 2 weeks prior to beginning this study.
- •5. Patient is currently participating or has participated in a study with an investigational
- •compound or device within 30 days (or 5 half-lives of the investigational compound)
- •of initial dosing with study drug.
- •6. Patients with active central nervous system (CNS) metastases and/or carcinomatous
- •meningitis are excluded. However, patients with CNS metastases who have
- •completed a course of therapy would be eligible for the study provided they are
- •clinically stable for 3 months prior to entry as defined as: (1) no evidence of new or
- •enlarging CNS metastasis (2) off steroids or on a stable dose of steroids.
- •7. Patient with a primary central nervous system tumor.
- •8. Patient has known hypersensitivity to the components of study drug or its analogs.
- •9. Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.
- •10. Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •11. Patient is, at the time of signing informed consent, a regular user (including recreational use) of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse.
- •12. Patient is pregnant or breastfeeding, or expecting to conceive within the projected
- •duration of the study.
- •13. Patient is known to be Human Immunodeficiency Virus (HIV)-positive.
- •14. Patient has active Hepatitis A, B or C.
- •15. Patient has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions is eligible.
- •16. Patient with a history of a prior malignancy with the exception of cervical
- •intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localizedprostate carcinoma with PSA <1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, or who is deemed at low risk for recurrence by his/her treating physician.
- •17. Patient is concurrently using growth hormone (GH), or growth hormone inhibitors.
研究者
相似试验
进行中（未招募）
不适用
An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung CancerEUCTR2007-005941-39-ATMerck Sharp & Dohme GmbH68
进行中（未招募）
1 期
An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Canceron-small cell lung cancerMedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-005941-39-DKMerck & Co. Inc.95
进行中（未招募）
不适用
A study comparing MK-0646 with Erlotinib for treatment of one type of lung cancerEUCTR2007-005941-39-SEMerck Sharp & Dohme (Sweden) AB95
进行中（未招募）
1 期
An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung CancerEUCTR2007-005941-39-FRaboratoires Merck Sharp & Dohme - Chibret95
进行中（未招募）
不适用
An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Canceron-small cell lung cancerMedDRA version: 9.1Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2007-005941-39-DEMerck & Co., Inc.211